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Abstract
Background: Colorectal cancer (CRC) infiltration by adaptive immune system cells correlates with favorable prognosis. The
role of the innate immune system is still debated. Here we addressed the prognostic impact of CRC infiltration by neutrophil
granulocytes (NG).
Methods: A TMA including healthy mucosa and clinically annotated CRC specimens (n = 1491) was stained with MPO and
CD15 specific antibodies. MPO+ and CD15+ positive immune cells were counted by three independent observers.
Phenotypic profiles of CRC infiltrating MPO+ and CD15+ cells were validated by flow cytometry on cell suspensions derived
from enzymatically digested surgical specimens. Survival analysis was performed by splitting randomized data in training
and validation subsets.
Results: MPO+ and CD15+ cell infiltration were significantly correlated (p,0.0001; r = 0.76). However, only high density of
MPO+ cell infiltration was associated with significantly improved survival in training (P= 0.038) and validation (P= 0.002)
sets. In multivariate analysis including T and N stage, vascular invasion, tumor border configuration and microsatellite
instability status, MPO+ cell infiltration proved an independent prognostic marker overall (P= 0.004; HR= 0.65; CI:60.15) and
in both training (P= 0.048) and validation (P= 0.036) sets. Flow-cytometry analysis of CRC cell suspensions derived from
clinical specimens showed that while MPO+ cells were largely CD15+/CD66b+, sizeable percentages of CD15+ and CD66b+
cells were MPO2.
Conclusions: High density MPO+ cell infiltration is a novel independent favorable prognostic factor in CRC.
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Introduction
Outgrowth and progression of human colorectal cancers (CRC)
are driven by gene mutations and microsatellite instability tumor
inherent characteristics [1,2], and by the interaction of cancer cells
with microenvironmental stimuli provided by non-transformed
cells [3,4]. In particular, cytokine and chemokine environment
and infiltration by immunocompetent cells significantly influence
CRC outcome [5–8].
Infiltration by activated CD8+ memory T cells and expression
of IFN-c gene within CRC were convincingly shown to be
associated with favorable prognosis [5,7]. Furthermore, we and
others have shown that FOXP3+ immune cell infiltration
independently predicts improved survival in CRC [9,10].
The role of innate immune system cells was not studied in
comparable detail and controversial data were reported regarding
CRC infiltration by NK cells [11–14] and macrophages [15–17].
Granulocytes have largely been disregarded by tumor immu-
nologists [18]. However, recent studies, mainly performed in
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experimental models, suggest that neutrophil granulocytes might
prevent metastatic cancer progression [19]. Furthermore, they
were suggested to undergo cytokine driven differentiation into N1
and N2 cells endowed with anti- and pro-tumor properties,
respectively [20,21]. These findings have led to a resurgent interest
in granulocyte infiltration in cancer [22–24].
In previous work, we showed that CRC infiltration by CD33+/
HLA-DR2/CD16+ myeloid cells is associated with improved
patient survival [13]. Based on these phenotypic features, we
hypothesized that CRC could be infiltrated by granulocytes with a
favorable prognostic significance.
Myeloperoxidase (MPO) is a lysosomal enzyme produced in
high amounts by neutrophilic granulocytes (NG) [25], especially
during their early maturation phase. MPO catalyzes the produc-
tion of hypochlorous acid from hydrogen peroxide and chloride
anion and oxidizes tyrosine to tyrosyl radicals. Both hypochlorous
acid and tyrosyl radicals are cytotoxic to a variety of microorgan-
isms. Notably, MPO is also involved in the induction of
granulocyte apoptosis following activation [26,27].
In a small series of CRC samples (n = 67), it has been shown
that MPO+ cell infiltration is significantly higher in CRC than
in normal colon mucosa [28]. However, prognostic relevance of
CRC infiltration by MPO+ cells has not been addressed so far.
CD15, also known as Lewis X and stage-specific embryonic
antigen 1, is a carbohydrate adhesion molecule expressed on
mature neutrophils, mediating phagocytosis and chemotaxis
[29]. Importantly, CD15 expression has been detected in tumor
cells and found to correlate with poor prognosis in head and
neck, gastric and lung cancers [30–32]. In CRC, expression of
CD15 on tumor cells was shown to occur during progression to
metastatic stages [33] and to be associated with high incidence
of recurrences and poor survival [34,35]. However, the
prognostic value of CRC infiltration by CD15+ immune cells
has not been explored.
Here we show for the first time that a subgroup of CRC is
characterized by a high infiltration by MPO+ and CD15+ positive
cells. Most importantly, high MPO+ cell density in CRC is
independently associated with favorable prognosis.
Materials and Methods
Ethics Statement
Written consent has been given from the patients for their
information to be stored in the hospital database and used for
research. The use of this clinically annotated TMA for research
was approved by the corresponding Ethics Committee of the
University Hospital of Basel (Ethikkommission beider Basel) and
the ex vivo analyses were approved by the Institutional Review
Board (63/07). For freshly excised clinical specimens included in
this study written consent has been given from the patients
undergoing surgical treatment at Basel University Hospital.
Tissue Microarray Construction
The TMA used in this work was constructed by using 1420 non-
consecutive, primary CRCs, as previously described [36]. Briefly,
formalin-fixed, paraffin-embedded CRC tissue blocks were
obtained. Tissue cylinders with a diameter of 0.6 mm were
punched from morphologically representative areas of each donor
block and brought into one recipient paraffin block (30625 mm),
using a semiautomated tissue arrayer. Each punch was made from
the center of the tumor so that each TMA spot consisted of at least
a 50% of tumor cells. One core per case was used.
Clinicopathological Features
Clinicopathological data for the 1420 CRC patients included in
the TMA were collected retrospectively in a non-stratified and
non-matched manner. Annotation included patient age, tumor
diameter, location, pT/pN stage, grade, histologic subtype,
vascular invasion, border configuration, presence of peritumoral
lymphocytic inflammation at the invasive tumor front and disease-
specific survival (table 1). Tumor border configuration and
peritumoral lymphocytic inflammation were evaluated according
to Jass using the original H&E slides of the resection specimens
corresponding to each tissue microarray punch [37]. The number
of lymph nodes evaluated ranged between 1 and 61 with mean
and median of 12 and 11, respectively. MMR status was evaluated
by IHC according to MLH1, MSH2 and MSH6 expression [38].
Based on this analysis, the TMA included 1031 MMR-proficient
tumors and 194 MMR-deficient tumors.
Overall survival was defined as primary endpoint. Follow-up
data were available for 1379 patients with mean/median and IQR
event-free follow-up time of 67.7/68 and 45–97 months.
Immunohistochemistry
Standard indirect immunoperoxidase procedures were used for
immunohistochemistry (IHC; ABC-Elite, Vector Laboratories,
Burlingame, CA). Briefly, slides were dewaxed and rehydrated in
distilled water. Endogenous peroxidase activity was blocked using
0.5% H2O2. Sections were incubated with 10% normal goat
serum (DakoCytomation, Carpinteria, CA) for 20 min and
incubated with primary antibody at room temperature. Primary
antibodies used were specific for MPO (clone 59A5 Novocastra,
Newcastle, UK), CD15 (clone Carb-1, Leica Biosystems, Nussloch,
Germany), CD16 (clone 2H7, Novocastra), CD68 (clone PG-M1,
Dako, Glostrup, Denmark), FOXP3 (clone 236A/E7, Abcam,
Cambridge, UK) and CD8 (clone C8/144B, DakoCytomation,
Switzerland). Subsequently, sections were incubated with perox-
idase-labelled secondary antibody (DakoCytomation) for 30 min
at room temperature. For visualization of the antigen, sections
were immersed in 3-amino-9-ethylcarbazole plus substrate-chro-
mogen (DakoCytomation) for 30 min, and counterstained with
Gill’s hematoxylin.
Evaluation of Immunohistochemistry
MPO+ and CD15+ tumor infiltrating cells were counted for
each punch (approximately one high power [20x] field) by a
trained research fellow [R.D.]. Data were independently validated
by two additional investigators [L.To. and C.H.] and a high
Spearman correlation coefficient ( = 0.82) and a highly significant
(p,0.0001) correlation between measurements was observed.
Evaluation of MLH1, MSH2, MSH6, CD16, CD68, CD8 and
FOXP3 specific stainings in the CRC TMA under investigation
was published previously [9,13,39].
Flow Cytometry Analyses
Following Institutional Review Board approval (63/07), tissues
from surgically removed CRC and adjacent normal mucosa were
minced, centrifuged, and resuspended in RPMI 1640 medium
supplemented with 5% foetal calf serum, 2 mg/ml collagenase IV,
0.1 mg/ml hyaluronidase V, and 0.2 mg/ml DNAse I (Sigma
Aldrich, Basel, Switzerland). Following a 1 hour digestion, cell
suspensions were filtered and centrifuged. For phenotypic analysis
of surface markers, cells were stained with mAbs for 15 minutes on
ice in PBS, washed once with PBS 0.5% FCS, 0.5 M EDTA buffer
and fixed in lysis buffer from BD Bioscience (1:10). Samples were
then permeabilized in BD fixation/permeabilization buffer. For
Prognostic Relevance of Granulocytes in CRC
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intracellular staining, an anti-MPO reagent or an isotype matched
negative control antibody were added for a 15 min incubation at
room temperature. After a PBS wash, cells were suspended in
wash buffer and analyzed by flow cytometry using a 2-laser BD
FACSCalibur (Becton Dickinson, San Jose, CA). Results were
analyzed by Cell Quest (Becton Dickinson, San Jose, CA) and
Flow Jo (Tree Star, Ashland, OR) softwares.
Statistical Analysis
Cut-off scores used to classify CRC with low or high MPO+ or
CD15+ infiltration were obtained by regression tree analysis,
evaluating sensitivity and false positive rate for the discrimination
of survivors and non-survivors, on all tumor samples [40]. Specific
scores were set at 60 cells/TMA-punch for MPO+ and at 46 cells/
TMA-punch for CD15+ infiltration. Chi-Square or Fisher’s Exact
tests were used to determine the association of MPO+ and CD15+
Table 1. Characteristics of CRC patient cohort (n = 1420)*.
Characteristics
Number of cases
or mean Percentage or range
Age, years 71 (30–96)
Tumor size (mm) 75 (4–170)
Gender
Female (%) 741 (52.2)
Male (%) 673 (47.4)
Anatomic site of the tumor
Left-sided (%) 912 (64.2)
Right-sided (%) 488 (34.4)
T stage
T1 (%) 62 (4.4)
T2 (%) 203 (14.3)
T3 (%) 899 (63.3)
T4 (%) 223 (15.7)
N stage
N0 (%) 711 (50.1)
N1 (%) 358 (25.2)
N2 (%) 294 (20.7)
Tumor grade
G1 (%) 31 (2.2)
G2 (%) 1177 (82.9)
G3 (%) 177 (12.5)
UICC
Stage I (pN0 pT1 or 2) (%) 185 (13.6)
Stage IIA (pN0 pT3)+IIB-C (pN0 pT4) (%) 445+61 (37.2)
Stage III (pN.0) (%) 581 (42.7)
Stage IV metastasis (%) 88 (6.5)
Tumor border configuration
Infiltrative (%) 871 (61.3)
Pushing (%) 513 (36.1)
Vascular invasion
No (%) 1002 (70.6)
Yes (%) 383 (27)
Microsatellite Stability
Proficient (%) 1031 (72.6)
Deficient (%) 194 (13.7)
Rectal cancers (%) 575 (40.5)
Overall survival time (months) 67.7 (0–152)
5-years survival % (95%CI) 56.4 (54–59)
*percentage may not add to 100% due to missing values of same variables; age and tumor size were evaluated using the Kruskal-Wallis test. Gender, anatomical site, T
stage, N stage, grade, vascular invasion, and tumor border configuration were analyzed using the x2 test. Survival analysis was performed using the Kaplan-Meier
method.
doi:10.1371/journal.pone.0064814.t001
Prognostic Relevance of Granulocytes in CRC
PLOS ONE | www.plosone.org 3 May 2013 | Volume 8 | Issue 5 | e64814
infiltration and clinicopathological features. Univariate survival
analysis was carried out by the Kaplan-Meier method and log rank
test. The assumption of proportional hazards was verified for both
markers by analyzing the correlation of Schoenfeld residuals and
the ranks of individual failure times. Any missing clinicopatholog-
ical information was assumed to be missing at random.
Subsequently, MPO+ and CD15+ cell infiltration data were
entered into multivariate Cox regression analysis and hazard ratios
(HR) and 95% confidence intervals (CI) were used to determine
associations with survival time. The multivariate Cox regression
analysis was performed with 975 cases since missing values were
excluded from the model.
Spearman’s rank correlation was used to analyze the correlation
between MPO+, CD15+, CD16+, CD68+, CD8+ and FOXP3+
cell infiltration. Statistical analyses were performed using R i386
Version 2.15.2 (http://www.R-project.org). Data reporting was
performed according to the REMARK criteria [41].
Results
CRC Infiltration by MPO+ and CD15+ Cells: Detection and
Association with Clinicopathological Features
MPO+ and CD15+ cells could be successfully identified in the
TMA under investigation by specific mAbs. Figure 1A–D shows
representative stainings of CRC with low and high MPO+ or
CD15+ cell infiltration.
Out of 1420 CRC individual specimens, MPO expression could
be evaluated in 1225 samples including 1031 MMR-proficient and
194 MMR-deficient CRC. CD15 expression was evaluable in
1191 CRC specimens, including 817 MMR proficient and 191
MMR deficient samples. Numbers of samples evaluated for each
feature are indicated in absolute numbers and percentages in
table 2. Dropouts were due to loss of punches during TMA
staining preparation or missing information, and usually account-
ed for ,15% of data (tables 1–2).
Normal colonic mucosa was indeed infiltrated by MPO+ and
CD15+ cells (mean: 6.4, median: 2, range 0–59 cells/punch for
MPO (n= 48) and mean: 4.3, median: 1, range 0–35 cells/punch
for CD15 (n= 47), respectively). However, a significantly higher
(P,0.001) infiltration by MPO+ and CD15+ cells was detectable
in CRC samples (mean: 26.7, median: 23, range 0–150 cells/
punch for MPO (n=1225) and mean: 16.4, median: 7, range 0–
125 cells/punch for CD15 (n= 1191), respectively; figure 1E–F).
MPO+ and CD15+ infiltration, as evaluated by absolute cell
numbers, was significantly higher in MMR deficient than in MMR
proficient CRC (median: 30 cells/punch in deficient vs. 21 cells/
punch in proficient CRC P=0.007 and 9 cells/punch in deficient
Figure 1. MPO and CD15 specific staining in CRC. CRC samples were stained with MPO and CD15 specific monoclonal antibodies (clone 59A5,
Novocastra and clone Carb-1, Leica, respectively). Tumor punches are representative of low (panels A and C) and high (panels B and D) density of CRC
infiltrating MPO+ (panels A–B) and CD15+ (panels C–D) cells, respectively. Magnification: 20x. Panel E reports the distribution of MPO+ cells in normal
mucosa (E1), total CRC (E2), MMR-deficient CRC (E3) and MMR-proficient CRC (E4). The green line indicates the cut-off of 60 cells/punch as defined by
regression tree analysis. Panel F reports the distribution of CD15+ cells in normal mucosa (F1), total CRC (F2), MMR-deficient CRC (F3) and MMR-
proficient CRC (F4). The green line indicates the cut-off of 46 cells/punch as defined by regression tree analysis.
doi:10.1371/journal.pone.0064814.g001
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vs 6 cells/punch in proficient CRC P=0.05, for MPO and CD15
respectively; figures 2E–F).
Regression tree analysis defined cut-off scores for MPO+ and
CD15+ CRC infiltrating cells detected in individual punch
biopsies (n = 60 and n= 46, respectively) were used to assess
clinicopathological correlations.
Univariate Cox regression analysis revealed that high density
MPO+ cell infiltration ($60 cells/punch), detectable in 14.5% of
tumors, was significantly associated with older age of patients
(P=0.04). Most importantly, it was significantly associated with
early (pT1–2) tumor stage (P=0.007), absence of local recurrence
(P=0.031) and higher 5-year survival rate (P=0.0009) (table 2).
High density of CD15+ infiltrating cells ($46 cells/punch),
detectable in 10.8% of tumors, was significantly associated with
left sided location (P=0.018), early (pT1–2) stage (P=0.0004),
absence of local recurrence (P=0.03) and higher 5-year survival
rate (P=0.033) (table 2).
Correlation between MPO+, CD15+, CD16+ and CD68+
Tumor-infiltrating Myeloid Cells
To explore relationships between tumor infiltration by cells
expressing MPO and other immune markers (CD15, CD16,
CD68, CD8, FOXP3) expressed by immunocompetent cells
infiltrating CRC, data from additional immune-histochemical
stainings of the same TMA from previous studies were used
[9,13,39]. The statistically strongest correlation was detectable
between MPO+ and CD15+ cell infiltration (r = 0.75, P,0.0001),
whereas correlations of lesser significance were detectable with
CD16+ (r = 0.32), CD68+ (r = 0.35), CD8+ (r = 0.13) and
FOXP3+ (r = 0.21) cell infiltration.
Ex vivo Characterization of MPO+ cells from Freshly
Removed CRC
To assess in detail phenotypic characteristics of tissue infiltrating
MPO+ cells, freshly excised CRC (n= 8) were enzymatically
digested, and single cell suspensions were analyzed by flow
cytometry. Examples of this phenotypic analysis are reported in
figure 2a.
Table 2. Association of MPO+ and CD15+ low and high immune cell density with clinicopathological features in CRC.
MPO2 MPO+ p-value CD15 – CD15+ p-value
N=1047 (85.4%) N=178 (14.5%) N=1062 (89.2%) N=129 (10.8%)
Age years 71 (30–96) 73 (37–96) 0.04 71 (30–96) 71 (38–96) 0.45
Tumor diameter mm 49 (8–120) 45 (4–170) 0.84 45 (4–160) 45 (8–170) 0.99
Gender Female 546 (52.1) 90 (50.6) 558 (52) 70 (54.3) 0.64
Male 501 (47.9) 88 (49.4) 0.75 515 (48) 59 (45.7)
Tumor location Left-sided 674 (64.4) 117 (65.7) 0.86 677 (63.1) 95 (73.6) 0.018
Right-sided 361 (34.5) 60 (33.7) 385 (35.9) 32 (24.8)
Histologic subtype Mucinous 86 (8.2) 16 (9) 0.66 97 (9) 7 (5.4) 0.19
Non-mucinous 955 (91.2) 158 (88.8) 965 (89.9) 122 (94.6)
pT stage pT1–2 182 (17.4) 48 (27) 0.007 190 (17.7) 41 (31.8) 0.0004
pT3–4 833 (79.6) 129 (72.5) 857 (79.9) 87 (67.4)
pN stage pN0 527 (50.3) 101 (56.7) 0.16 536 (50) 72 (55.8) 0.35
pN1-2 479 (45.7) 72 (40.4) 494 (46) 55 (42.6)
Tumor grade G1-2 894 (85.4) 146 (82) 0.224 907 (84.5) 110 (85.3) 0.68
G3 129 (12.3) 28 (15.7) 138 (12.9) 18 (14)
Vascular invasion Absent 740 (70.7) 133 (74.7) 0.27 754 (70.3) 102 (79.1) 0.07
Present 283 (27) 41 (23) 291 (27.1) 26 (20.2)
Tumor border Pushing 385 (36.8) 75 (42.1) 0.178 404 (37.7) 45 (34.9) 0.44
Infiltrating 637 (60.8) 99 (55.6) 640 (59.6) 83 (64.3)
PTL inflammation Absent 819 (78.2) 132 (74.2) 0.224 835 (77.8) 97 (75.2) 0.3
Present 205 (19.6) 42 (23.6) 211 (19.7) 31 (24)
Local recurrence Absent 212 (20.2) 54 (30.3) 0.031 241 (22.5) 26 (20.2) 0.03
Present 162 (15.5) 23 (12.9) 180 (16.8) 8 (6.2)
Distant metastasis Absent 304 (29) 69 (38.8) 0.108 343 (32) 32 (24.8) 0.08
Present 75 (7.2) 9 (5.1) 84 (7.8) 2 (1.6)
Microsatellite stability Deficient 159 (15.2) 35 (19.7) 0.161 167 (15.6) 24 (18.6) 0.45
Proficient 888 (86.1) 143 (13.9) 729 (67.9) 88 (68.2)
5-year survival rate (95%CI) 55.6 (52.4–59) 68.5 (61.3–76.5) 0.0009 56.8 (53.6–60.2) 63.6 (55.1–73.4) 0.033
*percentage may not add to 100% due to missing values of same variables; variables are indicated as absolute numbers, %, median or range; age and tumor size were
evaluated using the Kruskal-Wallis test. Gender, anatomical site, T stage, N stage, grade, vascular invasion, and tumor border configuration were analyzed using the x2
test. Survival analysis was performed using the Kaplan-Meier method.
doi:10.1371/journal.pone.0064814.t002
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The large majority of CRC infiltrating, MPO+ cells were
CD15+ (90.3%65.6%), CD16+, (77.6619.4%), and CD66b+
(80.6619.9%; figure 2b). Interestingly, MPO+ cells detectable in
autologous normal mucosa displayed a similar (P.0.05) marker
expression pattern (data not shown). Notably however, sizeable
percentages of MPO2/CD66b+ cells (47.3635.7%) and, more
expectedly, of MPO2/CD15+ cells (78.0617.7%) of possibly
cancerous nature were also detectable in CRC derived cell
suspensions.
Prognostic Significance of MPO+ and CD15+ Cell
Infiltration in the CRC Microenvironment
Median survival time was 50 and 46 months for patients with
high or low MPO+ cell density, respectively. High MPO+ cell
infiltration was significantly (P = 0.0003) associated with better
prognosis (0.59 HR, 95%CI: 0.45–0.74), as compared to tumors
with low MPO+ cell infiltration in univariate Cox regression
analysis. Upon splitting of the cohort in a test and a validation set,
high score MPO+ cell infiltration was still associated with
significantly improved survival (P=0.038 and P=0.002, respec-
tively; figure 3A–B). Several randomizations of the overall cohort
were tried and all results were found to be comparable.
In univariate analysis survival was also increased in case of high
score CD15+ cell infiltration (P=0.051, figure 3C). A combination
analysis however, showed that MPO is the dominant marker
associated with improved prognosis, without relevant additive
benefit provided by CD15 positivity (figure 3D).
Most importantly, in multivariate analysis, high score MPO+,
but not CD15+, cell infiltration was independently associated with
favorable prognosis after adjusting for several known prognostic
factors such as age, sex, T stage, N stage, tumor grade, vascular
invasion, tumor border configuration and microsatellite stability
(P=0.004; table 3). Also in the two stratified collectives the effect
of MPO+ cell infiltration on survival of patients with CRC
remained significant (P=0.048 and P=0.036 in the testing and
validation set, respectively).
Discussion
To the best of our knowledge, this is the first study identifying
MPO+ neutrophil granulocyte tumor infiltration as an indepen-
dent favorable prognostic factor in CRC.
Myeloid cell infiltration is known to promote tumor growth and
to be associated with poor prognosis in a variety of human cancers
[42]. In particular, tumor associated macrophages have been
indicated as obligate partners for tumor progression and metastasis
formation [43]. Granulocyte infiltration has also been found to be
associated with poor prognosis in different tumors including lung
cancers and renal and hepatocellular carcinoma [44–47]. In this
Figure 2. Phenotypic characterization of CRC infiltrating MPO+ cells. CRC surgical specimens were enzymatically digested and immediately
stained with fluorochrome labeled mAbs recognizing MPO, HLA-DR, CD66b, CD15 and CD16, as indicated in ‘‘materials and methods’’. Panel A
reports one representative staining, whereas panel B summarizes results from freshly excised specimens (n = 8) regarding the expression of the
indicated markers in CRC infiltrating MPO+ cells.
doi:10.1371/journal.pone.0064814.g002
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context, CRC might represent an interesting exception [48,49].
Indeed, controversial data have been reported on the prognostic
significance of macrophage infiltration in CRC [50–54].
Neutrophil infiltration has been found to be increased in the
transition from normal to dysplastic and cancerous mucosa [55].
Figure 3. Effects of MPO+ and CD15+ tumor infiltration on overall survival in patients with CRC. Kaplan-Meier overall survival curves
were designed according to MPO+ and CD15+ tumor infiltration in patients bearing CRC. In panels A–C, dotted lines refer to high density and black
lines to low density infiltration according to cut-off values established by regression tree analysis (60 cells/punch for MPO+ and 46 cells/punch for
CD15+ cell infiltration). Panels A and B report the effects of high MPO+ cell infiltration, as detected in the training (n = 609; 255 deaths observed in
519 patients with low CRC infiltration by MPO+ cells and 28 deaths observed in 90 patients with tumors with high MPO+ cell infiltration, P= 0.038)
and in the validation set (n = 583; 234 deaths observed in 498 patients with low CRC infiltration by MPO+ cells and 23 deaths observed in 85 patients
with tumors with high MPO+ cell infiltration, P=0.002). Panel C reports the effect of high CD15+ CRC infiltration in the whole group of patients under
investigation (n = 1169; 458 deaths observed in 1041 patients with low CRC infiltration by CD15+ cells and 47 deaths observed in 128 patients with
tumors with high CD15+ cell infiltration, P= 0.051). In panel D cumulative effects of tumor infiltration by MPO+ and CD15+ cells were explored. Rosa
line (430/946) refers to tumors with low MPO+/CD15+ cell infiltration. Light blue line (18/34) refers to tumors with low MPO+ and high CD15+ cell
infiltration. Lila line (29/91) refers to tumors with high MPO+/CD15+ cell infiltration and green line (18/76) refers to CRC with high MPO+ and low
CD15+ cell infiltration (n = 1147; 430 deaths observed in 946 patients with low CRC infiltration by MPO+ and CD15+ cells; 18 deaths observed in 34
patients with tumors with high CD15+ and low MPO+ cell infiltration; 29 deaths observed in 91 patients with high CRC infiltration by MPO+ and
CD15+ cells; 18 deaths observed in 76 patients with tumors with high MPO+ and low CD15+ cell infiltration, P=0.002).
doi:10.1371/journal.pone.0064814.g003
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PLOS ONE | www.plosone.org 7 May 2013 | Volume 8 | Issue 5 | e64814
Furthermore, CRC infiltration by CD66b+ cells has recently been
proposed to be associated with adverse prognosis [56].
In previous work we showed that CRC infiltration by CD16+
cells correlates with improved survival [13]. This marker is
expressed in neutrophils, in a subset of macrophages and in NK
cells [57,58]. Indeed, NK cell infiltration in CRC is negligible
[13,14] and devoid of prognostic significance [59]. Since CRC
infiltrating CD16+ cells are also CD11b+/CD33+/HLA-DR-, in
this study we focused on the analysis of cells expressing MPO and
CD15 granulocyte markers.
In univariate analysis high density CRC infiltration by cells
expressing either marker was associated with improved survival.
However, following adjustment for multiple comparisons carried
out to compensate for the exploratory nature of this analysis this
favorable prognostic relevance was maintained for MPO+ but not
for CD15+ cell infiltration.
Importantly, in accord with a previously published report [55]
we observed that MPO+ and CD15+ cells preferentially colonized
CRC tissues while they poorly infiltrated normal colon mucosa,
suggesting that they might be specifically recruited to the tumor
microenvironment. Interestingly, MPO+ cell infiltration was
higher in MMR-deficient than in MMR-proficient CRC as
previously suggested by a study conducted with 67 samples from
a limited number of cancers (n = 35) [28].
Flow-cytometric analysis of digested paired normal and
cancerous tissues indicates that in both healthy mucosa and
CRC infiltrating MPO+ cells are CD15+/CD16+/CD66b+/
HLA-DR-, consistent with a granulocytic lineage. Most impor-
tantly however, we observed substantial percentages of CD66b+/
MPO- cells infiltrating CRC. These data might explain the
discrepancies between our findings and a previous report focusing
on CD66b+ CRC infiltrating cells [56]. Notably, neutrophils with
similar phenotypic characteristics have also been found to infiltrate
head and neck cancers [60].
Similarly, the presence of CD15+/MPO2 cells in healthy
mucosa and cancerous tissues might explain the differential
prognostic relevance of these markers. Notably however, MPO
gene expression was undetectable in CRC or normal mucosa
specimens (data not shown) consistent with a mature granulocyte
nature of MPO+ infiltrating cells [61].
MPO activity has been suggested to contribute to the
pathogenesis of degenerative diseases, including atherosclerosis,
multiple sclerosis and Alzheimer disease [62]. Furthermore, high
MPO activity or MPO+ cell infiltration have been detected in
esophageal [63], and gynecological cancers [64,65] and in CRC
[28,66,67], but their prognostic impact was not analyzed.
Despite early reports documenting their ability to mediate
tumor cell cytotoxicity [68] granulocytes have largely been
neglected by tumor immunologists [18]. However experimental
models in the past have indicated that colorectal cancer cells
transfected with G-CSF gene can be rejected by tumor infiltrating
neutrophils upon interaction with IFN-c producing T cells [69].
Granulocytes were also shown to express co-stimulatory molecules
and to be able to present antigens [70,71], thus suggesting the
possibility of a role in the initiation of antigen specific antitumor
responses.
More recently, evidence of the ability of granulocytes to inhibit
lung metastasis formation in an experimental breast cancer model
was provided [19]. Furthermore, the capacity of granulocytes to
undergo TGF-b dependent polarization into N1 and N2
functional profiles, characterized by anti- or pro-tumoral proper-
ties, respectively, similarly to macrophages, has also been
documented [20].
The molecular background underlying CRC infiltration by
MPO+ cells and its prognostic significance is unclear. These
phenomena could reflect chemokine production by activated T
cells, and therefore indirectly result from ongoing antitumoral
adaptive responses. Alternatively, they might be related to the
production of granulocyte attracting chemokines by tumor cells.
At least CXCL8 (IL-8) is known to be produced by CRC cells.
However, its production was suggested to be associated with
increased angiogenesis and tumor dissemination [72]. On the
other hand, we and others have previously shown that GM-CSF,
promoting granulocyte maturation and survival, can also be
produced by CRC cells [73,74].
Our results contribute to the characterization of the complex
features inherent in gut microenvironment and with CRC-
immune system interaction [75]. Further research is warranted
to clarify molecular mechanisms underlying the independent
prognostic impact of MPO+ cells in CRC. Importantly, here we
show that CRC infiltrating MPO+ cells express CD16 Fcc
intermediate affinity receptor. The ability of granulocytes to
mediate antibody dependent cellular cytotoxicity (ADCC) is
debated. However, the availability of novel therapeutic mAb with
glycoengineered Fc fragments characterized by increased affinity
Table 3. Multivariate Hazard Cox regression survival analysis.
HR (95% CI) P-Values
MPO (low vs high) 0.65 (0.5–0.8) 0.004
Age (continuous) 1.03 (1.02–1.03) ,0.0001
Gender (men vs women) 1.21 (1.16–1.26) ,0.0001
pT stage (1,2,3,4) 1.79 (1.71–1.87) ,0.00001
pN stage (0,1,2) 1.93 (1.87–1.99) ,0.0001
Tumor Grade (1,2,3) 1.23 (1.10–1.36) 0.11
Vascular invasion (0,1)* 1.43 (1.33–1.53) 0.0006
Tumor border configuration (0,1)** 1.52 (1.41–1.63) 0.0003
Microsatellite stability (deficient vs. proficient) 1.70 (1.56–1.84) 0.0002
Multivariate analyses showing Hazard Ratios and p-value for all CRC (n = 975, due to missing values, see ‘‘materials and methods’’) conferred by high MPO density, age,
sex, tumor size, nodal status, tumor grade, vascular invasion, tumor border configuration and microsatellite stability.
*0: absent, 1: present.
**0: pushing, 1: infiltrating.
doi:10.1371/journal.pone.0064814.t003
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for Fcc receptors [76] might lead to a reevaluation of the effector
significance of granulocytes.
Within this framework, it is tempting to speculate that
neutrophil infiltration should be included in current prognostic
models for CRC [77] and that it might represent an important
novel stratification factor for randomization in specific clinical
trials.
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